Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Bolt Biotherapeutics Inc BOLT

Healthcare Biotechnology
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company’s pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2... see more

Recent & Breaking News (NDAQ:BOLT)

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

GlobeNewswire March 12, 2026

Bolt Biotherapeutics to Participate in Upcoming March Conferences

GlobeNewswire February 24, 2026

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire November 12, 2025

Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027

GlobeNewswire October 1, 2025

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire August 14, 2025

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire May 12, 2025

Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

GlobeNewswire May 8, 2025

Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody(TM) ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025

GlobeNewswire April 30, 2025

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

GlobeNewswire April 25, 2025

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

GlobeNewswire March 25, 2025

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

GlobeNewswire March 24, 2025

Bolt Biotherapeutics to Participate in Upcoming March Conferences

GlobeNewswire February 25, 2025

Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.

GlobeNewswire February 11, 2025

Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire November 12, 2024

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

GlobeNewswire November 7, 2024

Bolt Biotherapeutics, Inc. May Have Violated Securities Laws And Shareholders Are Urged To Participate In A Case With The Schall Law Firm

ACCESS Newswire September 6, 2024

The Schall Law Firm Invites Investors To Contribute To A Securities Fraud Lawsuit Against Bolt Biotherapeutics Inc

ACCESS Newswire September 5, 2024

Bolt Biotherapeutics Announces Changes to its Board of Directors

GlobeNewswire September 4, 2024

Bolt Biotherapeutics Inc. May Have Violated Securities Regulations And Stakeholders Are Urged To Reach Out To The Schall Law Firm

ACCESS Newswire September 4, 2024

BOLT DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action - BOLT

Newsfile September 3, 2024

Podcasts